Retrospective analyses in this study showed that patients with a PIK3CA mutation detected in ctDNA benefit more from addition of alpelisib compared to all patients in which PIK3CA mutations were detected in tumor tissue (primary tumor or metastasis) [51]. The gene discussed is PIK3CA; the disease is neoplasm.